yanhaijin:Tekmira merges with firm developing HBV cure With the objective of creating an all-oral cure for hepatitis B infection, Tekmira Pharmaceuticals (NASDAQ:TKMR) merges with Doylestown, PA-based OnCore Biopharma.-----TKMR是HBV领域的新锐?ARWR的未来如何?继续跟踪。